GlassScriptPhysician profile
Edgar Moreno
NPI 1003381583
$6,832.38
in general payments reported to CMS, 2019-2025
35 companies · $4,258 in 2025
The $4,258 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $57.02 · 2022: $223 · 2023: $249 · 2024: $2,046 · 2025: $4,258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,073 · Travel and Lodging: $1,349 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,072.86 |
| Travel and Lodging | $1,348.56 |
| Education | $131.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,503.23 | 2024-2025 | Minimed 780g |
| Novo Nordisk INC | $735.34 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $720.43 | 2021-2025 | Tepezza, Evenity, Repatha |
| Xeris Pharmaceuticals, INC. | $566.27 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Lilly USA, LLC | $390.21 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Ascensia Diabetes Care US INC. | $298.04 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $197.50 | 2022-2024 | Farxiga |
| Abbvie INC. | $144.15 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $119.36 | 2025 | |
| Corcept Therapeutics | $110.20 | 2024-2025 | Korlym |
| Astellas Pharma US INC | $99.00 | 2025 | |
| Mannkind Corporation | $97.27 | 2024-2025 | |
| Dexcom, INC. | $89.09 | 2025 | Dexcom G6 Transmitter |
| Recordati_rare_diseases_inc. | $80.86 | 2025 | Isturisa |
| Antares Pharma, INC. | $74.79 | 2024-2025 | Xyosted |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.68 | 2024-2025 | Jardiance |
| Tandem Diabetes Care, INC. | $54.68 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Otsuka America Pharmaceutical, INC. | $51.45 | 2022-2023 | Rexulti |
| Alexion Pharmaceuticals, INC. | $43.08 | 2024-2025 | Strensiq |
| Kyowa Kirin, INC. | $41.57 | 2025 | |
| Echosens North America, INC. | $39.91 | 2025 | Fibroscan |
| Currax Pharmaceuticals LLC | $31.96 | 2024-2025 | Contrave |
| Chiesi USA, INC. | $29.80 | 2025 | Mycapssa |
| Cequr Corporation | $28.59 | 2023 | Cequr Simplicity |
| Ascendis Pharma Endocrinology INC | $24.42 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $24.36 | 2024 | Crysvita |
| Averitas Pharma INC. | $23.55 | 2024 | Qutenza |
| Vertex Pharmaceuticals Incorporated | $22.95 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.80 | 2024 | |
| Amphastar Pharmaceuticals, INC. | $22.60 | 2025 | |
| Pfizer INC. | $16.84 | 2023 | |
| Tolmar, INC. | $16.57 | 2025 | Jatenzo |
| Biohaven Pharmaceuticals, INC. | $16.24 | 2021 | |
| Radius Health, INC. | $15.93 | 2024 | |
| Tactile Systems Technology INC | $11.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edgar Moreno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.